Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC. Issue 5 (May 2015)

• Record Type: Journal Article
• Authors: van den Berg, Liseth L.; Klinkenberg, Theo J.; Groen, Harry J. M.; Widder, Joachim
• Is Part Of: Journal of thoracic oncology. Volume 10:Issue 5(2015)
• Publication Date: 2015-05
• Subjects: Non–small-cell lung cancer -- Early stage NSCLC -- Lobectomy -- Stereotactic radiotherapy; Chest -- Cancer -- Periodicals; Thoracic Neoplasms -- Periodicals; 616.99494005
• DOI: 10.1097/JTO.0000000000000483
• Languages: English
• ISSNs: 1556-0864

Abstract

Abstract : Introduction: Surgery is the standard treatment for early stage non–small-cell lung cancer (NSCLC). For medically inoperable patients, stereotactic ablative radiotherapy (SABR) has emerged as widely used standard treatment. The aim of this study was to analyze survival and patterns of tumor recurrence in patients with clinical stage I NSCLC treated with surgery or SABR. Methods: Clinical data from all subsequent fluoro-deoxyglucose positron emission tomography/computed tomography-based stage I NSCLC patients (cT1-T2aN0M0) treated with surgery or SABR at our center between 2007 and 2010 were collected. Primary endpoints were overall survival and tumor recurrences/new primary lung tumors. Treatment groups were compared using multivariable Cox regression and competing risk analyses. Results: Three hundred-forty patients treated with surgery ( n = 143) or SABR ( n = 197) were included. Surgical patients were younger, had a better WHO performance status and less comorbidities. After adjustment for prognostic covariables, treatment did not influence overall survival (adjusted hazard ratio [HR], SABR versus surgery 1.07; 95% confidence interval [CI]: 0.74–1.54; p = 0.73). Local control and distant recurrence were equal, whereas locoregional recurrences were significantly more frequent after SABR compared with surgery (adjusted sub-HR 2.51; 95% CI: 1.10–5.70; p = 0.028). Nodal failure (HR: 2.16; 95% CI: 1.34–3.48) and distant metastases (HR: 2.12; 95% CI: 1.52–2.97), but not local failure (HR: 1.00; 95% CI: 0.53–1.89) predicted overall survival. Conclusions: In patients with fluoro-deoxyglucose positron emission tomography/computed tomography-based stage I NSCLC, SABR confers worse locoregional tumor control because of more nodal failures compared with surgery, stressing the need to improve mediastinal and hilar staging.